İki uçlu depresyonun farmakolojik tedavisinde yenilikler

Year 2013, Volume: 3 Issue: 5, 0 - 0, 01.05.2013

Yasin Bez

Abstract

s of the Speakers / Konuşmacı leri

Keywords

-

İki uçlu depresyonun farmakolojik tedavisinde yenilikler

Abstract

tedavisinde kullanımı çok uzun yıllara dayansa da bu konudaki araştırmalar oldukça azdır. 1990’ların başına kadar yapılmış bazı açık etiketli çalışmalar ve olgu serileri faydalı olabileceklerini bil- dirmiştir. Daha sonraki yıllarda metilfenidat ile ilgili yapılan hem prospektif hem de geriye dönük desende yapılan çalışmalar da açık etiketli olmuştur. Güncel literatür bu ajanların iki uçlu dep- resyonda kullanımı ile ilgili randomize kontrollü çalışmalardan hala yoksundur (40). Mizaç dengeleyicilere yetersiz yanıtı olan 85 iki uçlu depresyon hastası ile yapılmış plasebo kontrollü ekleme tedavisini test eden bir çalışma modafinil kullanan hastalarda daha yüksek antidepresif yanıt bildirmiştir. Tedaviye ikincil hipomani veya mani açısından modafinil plaseboya eşdeğer bul- muştur (41). Bu alanda yayınlanmış en yeni randomize kontrollü çalışma lityum, olanzapin veya valproik asit kullanmakta olan 258 iki uçlu I depresyon hastasında plaseboya karşı armodafinil eklemenin depresif belirtileri iyileştirmede daha üstün olduğunu göstermiştir (42). Tüm çalışmalar birlikte ele alındığında iki uçlu depresyon tedavisinde ekleme stimülan kullanımının yorgunluk, uykuya meyil ve bilişsel problemlere genel olarak faydalı olduğu, etkilerinin 1-2 hafta gibi kısa bir sürede başladığı ve erken dönemde yanıtın varlığının devam edecek iyileşmenin de haber

Keywords

-

References

• Judd LL, Akiskal HS, Schetter PJ, Endicott J, Maser J, Solomon DA Leon AC, Rice JA, Keller MB. The long-term natural history of weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7.
• Judd LL, Akiskal HS, Schetter PJ, Coryell W, Endicott J, Maser JD Solomon DA, Leon AC, Keller MB. . A prospective investigation of natural history of long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-9.
• Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS Frye MA, Keck PE Jr, McElroy SL, Grunze H, Post RM. Three times more days depressed than manic or hypomanic in both bipolar I and II disorder. Bipolar Disord 2007;9:531-5.
• Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000; 61:804-8.
• Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, Bowden CL, Sachs GS, Nierenberg AA; STEP-BD Investigators. Longterm implications of early onset bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004; 55:875-81.
• Beesdo K, Höfler M, Leibenluft E, Lieb R, Bauer M, Pfennig A. Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life. Bipolar Disord 2009; 11:637-49.
• Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic medication drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58:85-91.
• Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 2008; 59:1175-83.
• Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and metaanalysis of the evidence. Bipolar Disord 2010;12:1-9.
• Goodwin FK, Jamison KR. Course and outcome. In: Manic-Depressive Illness-Bipolar Disorder and Recurrent Depression. New York, Oxford University Press, 2007:119-54.
• Colom F, Vieta E, Daban C, Pacchiarotti I, Sanchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006; 93:13-7.
• Chisholm D, van Ommeren M, Ayuso-Mateos JL, Saxena S. Costeffectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry 2005; 187:559-567.
• Smith LA, Cornelius VR, Azorin JM, Perungi G, Vieta E, Young AH Bowden CL. Valproate fort he treatment of acute bipolar depression: Systematic review and meta-analysis. J Affect Disord 2010;122:1-9.
• Chang JS, Ha K. Management of bipolar depression. Indian J Psychol Med 2011; 33(1):11-17.
• Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009;194:4-9.
• Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-50.
• Yildiz A, Sachs GS. Do antidepressants induce rapid cycling? A genderspecific association. J Clin Psychiatry 2003;64:814-8.
• Strejilevich SA, Martino DJ, Marengo E, Igoa A, Fassi G, Whitham EA, Ghaemi SN. Long-term worsening of bipolar disorder related with frequency of antidepressant exposure. Ann Clin Psychiatry 2011;23:186-92. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikelea JM, Kaprinis GS. Treatment guidelines for bipolar depression: a critical review. J Affect Disord 2005;86:1-10.
• Baldassano CF, Hosey A, Coello J. Bipolar depression: An evidence-based approach. Bipolar Disord 2011; 13:483-7.
• Sachs G, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME.. Effectiveness of adjunctive antidepressant treatment in bipolar depression. N Engl J Med 2007;356:1711-22.
• Ahn YM, Nam JY, Culver JL, Marsh WK, Bonner JC, Ketter TA. Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression. Ann Clin Psychiatry 211;23:17-24. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin psychiatry 2004; 65:1715-9.
• Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtova O, Vanderburg DG, Kasuba B. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, plasebo-controlled trial. J Clin Psychiatry 2011;72:1413-22. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R. Aripiprazole monotherapy in non-psychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20.